|
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine Clinical research trials and A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine. A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine clinical trial. Participants frequently get the best healthcare available for their A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine  A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine
For Condition: Toxoplasmosis, Cerebral,HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis. To evaluate the efficacy of 566C80 in the acute treatment and suppression of CNS toxoplasmosis in AIDS patients who fail or who cannot tolerate conventional therapy.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have the following: - Presumptive diagnosis of AIDS. - Cerebral toxoplasmosis. - Expected survival of at least four weeks without therapy. - Willing and able to give informed consent. Prior Medication: Allowed: - Pyrimethamine-sulfonamide. - Clindamycin-sulfonamide. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Significant emotional disorder or psychosis. - Evidence of significant malabsorption, ileus or significant emesis at entry which would inhibit drug absorption. - Other known central nervous system lesions such as lymphoma, tuberculoma, cryptococcoma, active neurosyphilis. Unwilling or unable to take 566C80 with a meal, enteral supplements (eg: - Ensure Plus) or pulverized form through a nasogastric tube. - Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen. Concurrent Medication: Excluded: - Drugs with potential anti-toxoplasmosis activity including sulfone, sulfonamide, trimethoprim, pyrimethamine and clindamycin during the acute therapy phase of the trial. - First three weeks of treatment: - Retrovir (zidovudine) or any investigational agent including antiretroviral agents (eg: - ddI,ddC). Patients with the following are excluded: - Significant emotional disorder or psychosis. - Evidence of significant malabsorption, ileus or significant emesis at entry which would inhibit drug absorption. - Other known central nervous system lesions such as lymphoma, tuberculoma, cryptococcoma, active neurosyphilis. Unwilling or unable to take 566C80 with a meal, enteral supplements (eg: - Ensure Plus) or pulverized form through a nasogastric tube. - Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen. Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen.
Total Enrollment:
Location and Contact Information:
Saint Vincent's Hosp and Med Ctr
New York City, New York, 10011
United States
Georgetown Univ Med Ctr
Washington D.C., District of Columbia, 20007
United States
Southern Alberta HIV Clinic / Foothills Hosp
Calgary, Alberta,
Canada
Infectious Disease Physicians Inc
Annandale, Virginia, 22203
United States
Wellesley Hosp
Toronto, Ontario,
Canada
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, 97210
United States
Infectious Disease Med Group
Oakland, California, 94609
United States
Johns Hopkins Hosp
Baltimore, Maryland, 21205
United States
Gathe, Joseph, M.D.
Houston, Texas, 77004
United States
Dr Emil Toma / Hotel Dieu de Montreal
Montreal, Quebec,
Canada
Baylor College of Medicine
Houston, Texas, 77030
United States
Los Angeles County - USC Med Ctr
Los Angeles, California, 90033
United States
Davies Med Ctr
San Francisco, California, 94114
United States
Harlem Hosp Ctr
New York City, New York, 10037
United States
UCSF - San Francisco Gen Hosp
San Francisco, California, 94110
United States
Dr Julio S G Montaner
Vancouver, British Columbia,
Canada
Infectious Disease Research Consortium of Georgia
Atlanta, Georgia, 30345
United States
San Francisco Gen Hosp
San Francisco, California, 941102859
United States
Beth Israel Med Ctr
New York City, New York, 10003
United States
SUNY / Health Sciences Ctr at Stony Brook
Stony Brook, New York, 117948153
United States
Regional Med Ctr at Memphis
Memphis, Tennessee, 38103
United States
Duke Univ Med Ctr
Durham, North Carolina, 27710
United States
Additional Information:
Study ID Numbers: 101A; 02
Study Start Date:
Record last reviewed: March 1992
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001994
Other Toxoplasmosis, Cerebral Studies:
1. A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS
2. Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
3. A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients with AIDS
4. A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine
5. A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
Related Studies:
Other Toxoplasmosis, Cerebral Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or are Intolerant of Pyrimethamine-Sulfadiazine
|
|
|
|
|
|
|
|
